Radix Hedysari polysaccharide suppresses lipid metabolism dysfunction in a rat model of non-alcoholic fatty liver disease via adenosine monophosphate-activated protein kinase pathway activation

Molecular Medicine Reports

Volumn 10, Issue 3, 2014, Pages 1237-1244

  Sun, Wei Ming ^a   Wang, Yu Ping ^a   Duan, Yong Qiang ^a,b   Shang, Hong Xia ^b   Cheng, Wei Dong ^a,c  

^a LANZHOU UNIVERSITY   (China)

^b GANSU UNIVERSITY OF CHINESE MEDICINE   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Adenosine monophosphate activated protein kinase pathway; Lipid metabolism; Non alcoholic fatty liver disease; Polysaccharide; Radix hedysari

Indexed keywords

ANTILIPEMIC AGENT; HEDYSARUM ROOT POLYSACCHARIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; LIVER PROTECTIVE AGENT; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; POLYSACCHARIDE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; ANTIOXIDANT; PLANT EXTRACT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HEPATITIS; LIPID DIET; LIPID LIVER LEVEL; LIPOGENESIS; LIPOLYSIS; LIVER HISTOLOGY; LIVER INJURY; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLANT ROOT; PROTEIN EXPRESSION; RADIX HEDYSARI; RAT; RAT MODEL; REDUCTION; UPREGULATION; ACONITE; ADVERSE EFFECTS; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ACONITUM; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIOXIDANTS; BODY WEIGHT; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HYPOLIPIDEMIC AGENTS; LIPOGENESIS; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PLANT EXTRACTS; POLYSACCHARIDES; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTORS;

EID: 84905455008     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2327     Document Type: Article

References (31)

1. Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112, 2006.
2. Targher G: Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabetic Med 24: 1-6, 2007.
3. Koot BG, van der Baan-Slootweg OH, Tamminga-Smeulders CL, et al: Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement. Arch dis Child 96: 669-674, 2011.
4. Park HJ, DiNatale DA, Chung MY, et al: Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J Nutr Biochem 22: 393-400, 2011.
5. Quan HY, Kim do Y, Kim SJ, Jo HK, Kim GW and Chung SH: Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem Pharmacol 85: 1330-1340, 2013.
6. Wei D, Cheng W, Wei Y and Zhang L: Phosphorylated modification and in vitro antioxidant activity of Radix Hedysari polysaccharide. Glycoconj J 29: 167-172, 2012.
7. Hui HP, Feng SL, Hu FD, Cui F and Wu YQ: Study on antioxidative activity of polysaccharide from radix hedysari in vitro. J Anhui Agri Sci 38: 4056-4057, 2010.
8. Liu J, Deng W, Fan L, et al: The role of radix hedysari polysaccharide on the human umbilical vein endothelial cells (HUVECs) induced by high glucose. Eur J Intern Med 23: 287-292, 2012.
9. Wei D, Wei Y, Cheng W and Zhang L: Sulfated modification, characterization and antitumor activities of Radix hedysari polysaccharide. Int J Biol Macromol 51: 471-476, 2012.
10. Grasselli E, Voci A, Canesi L, et al: Direct effects of iodothyronines on excess fat storage in rat hepatocytes. J Hepatol 54: 1230-1236, 2011.
11. Koopman R, Schaart G and Hesselink MK: Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem Cell Biol 116: 63-68, 2001. (Pubitemid 32695819)
12. Bligh EG and Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
13. Wang YP, Huang LY, Sun WM, et al: Insulin receptor tyrosine kinase substrate activates EGFR/ERK signalling pathway and promotes cell proliferation of hepatocellular carcinoma. Cancer Lett 337: 96-106, 2013.
14. Huang LY, Wang YP, Wei BF, et al: Deficiency of IRTKS as an adaptor of insulin receptor leads to insulin resistance. Cell Res 23: 1310-1321, 2013.
15. Saltiel AR and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001. (Pubitemid 34000783)
16. Duvnjak M, Lerotic I, Barsic N, Tomasic V, Virovic Jukic L and Velagic V: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13: 4539-4550, 2007. (Pubitemid 47455230)
17. Xiao J, Guo R, Fung ML, Liong EC and Tipoe GL: Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Pancreat Dis Int 12: 125-135, 2013.
18. Sakata R, Nakamura T, Torimura T, Ueno T and Sata M: Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: a double-blind placebo-controlled study. Int J Mol Med 32: 989-994, 2013.
19. Vuppalanchi R and Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49: 306-317, 2009.
20. Musso G, Cassader M and Gambino R: Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 22: 489-496, 2011.
21. Matthew Morris E, Fletcher JA, Thyfault JP and Rector RS: The role of angiotensin II in nonalcoholic steatohepatitis. Mol Cell Endocrinol 378: 29-40, 2013.
22. Kato J, Koda M, Kishina M, et al: Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. Int J Mol Med 30: 107-113, 2012.
23. Leuschner UF, Lindenthal B, Herrmann G, et al: High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2: 472-479, 2010.
24. Malaguarnera M, Gargante MP, Russo C, et al: L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am J Gastroenterol 105: 1338-1345, 2010.
25. Long YC and Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Inv 116: 1776-1783, 2006.
26. Gray S and Kim JK: New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab 22: 394-403, 2011.
27. Kawaguchi T, Osatomi K, Yamashita H, Kabashima T and Uyeda K: Mechanism for fatty acid 'sparing' effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. J Biol Chem 277: 3829-3835, 2002. (Pubitemid 34968632)
28. Zhou G, Myers R, Li Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001. (Pubitemid 32995375)
29. Yoshimura Y, Nishii S, Zaima N, Moriyama T and Kawamura Y: Ellagic acid improves hepatic steatosis and serum lipid composition through reduction of serum resistin levels and transcriptional activation of hepatic ppara in obese, diabetic KK-A(y) mice. Biochem Biophys Res Commun 434: 486-491, 2013.
30. Xu X, So JS, Park JG and Lee AH: Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis 33: 301-311, 2013.
31. Lee JH, Moon MH, Jeong JK, et al: Sulforaphane induced adipolysis via hormone sensitive lipase activation, regulated by AMPK signaling pathway. Biochem Biophys Res Commun 426: 492-497, 2012.